Inclusion Criteria

-INCLUSION CRITERIA:

1. Metastatic cancer that expresses carcinoembryonic antigen (CEA) as assessed by one of
the following methods:

- Immunohistochemistry of resected tissue, assessed by immunohistochemistry (IHC)
in the Clinical Laboratory Improvement Amendments (CLIA) approved test in the
Laboratory of Pathology, Center for Cancer Research (CCR), National Cancer
Institute (NCI), National Institutes of Health (NIH). Since the affinity of the
antibody is weak, a result of greater than or equal to 1+ is considered
positive.

- Detection of elevated levels of circulating CEA using a standard clinical
enzyme-linked immunosorbent (ELISA) assay. Results will be considered positive
if CEA level is greater than 10 mcg/L.

- Metastatic cancer diagnosis will be confirmed by the Laboratory of Pathology at
the NCI.

2. Hepatic metastases must represent the life limiting components of the disease defined
as liver disease with a very high likelihood of causing the death of a patient
according to the best clinical judgment of the attending physician.

3. Patients must have previously received systemic standard care (or effective salvage
chemotherapy regimens) for metastatic disease, if known to be effective for that
disease, and have been either non-responders (progressive disease) or have recurred.

4. Greater than or equal to 18 years of age.

5. Willing to sign a durable power of attorney

6. Able to understand and sign the Informed Consent Document

7. Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1.

8. Life expectancy of greater than three months.

9. Patients of both genders must be willing to practice birth control from the time of
enrollment on this study and for up to four months after receiving the preparative
regimen.

10. Patients must be human leukocyte antigen (HLA-A*0201) positive

11. Serology:

1. Seronegative for human immunodeficiency virus (HIV) antibody. (The experimental
treatment being evaluated in this protocol depends on an intact immune system.
Patients who are HIV seropositive can have decreased immune-competence and thus
be less responsive to the experimental treatment and more susceptible to its
toxicities.)

2. Seronegative for hepatitis B antigen and hepatitis C antibody unless antigen
negative.

12. Hematology:

1. Absolute neutrophil count greater than 1000/mm^3 without the support of
filgrastim.

2. White blood cell (WBC) (greater than 3000/mm^3.

3. Platelet count greater than 100,000/mm^3.

4. Hemoglobin greater than 8.0 g/dl.

13. Chemistry:

1. Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less or
equal to 2.5 times the upper limit of normal.

2. Serum creatinine less than or equal to 1.6 mg/dl.

3. Total bilirubin less than or equal to 1.5 mg/dl, except in patients with
Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dl.

14. More than four weeks must have elapsed since any prior systemic therapy at the time
the patient receives the preparative regimen, and patients' toxicities must have
recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo).

EXCLUSION CRITERIA:

1. Women of child-bearing potential who are pregnant or breastfeeding because of the
potentially dangerous effects of the preparative chemotherapy on the fetus or infant.

2. Active systemic infections, coagulation disorders or other major medical illnesses of
the cardiovascular, respiratory or immune system, myocardial infarction, cardiac
arrhythmias, obstructive or restrictive pulmonary disease.

3. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency
Disease).

4. Concurrent opportunistic infections (The experimental treatment being evaluated in
this protocol depends on an intact immune system. Patients who have decreased immune
competence may be less responsive to the experimental treatment and more susceptible
to its toxicities).

5. Concurrent systemic steroid therapy

6. History of severe immediate hypersensitivity reaction to any of the agents used in
this study.

7. History of coronary revascularization or ischemic symptoms

8. Any patient known to have an left ventricular ejection fraction (LVEF) less than or
equal to 45%.

9. Documented LVEF of less than or equal to 45% tested in patients with:

1. History of ischemic heart disease, chest pain, or clinically significant atrial
and/or ventricular arrhythmias including but not limited to: atrial
fibrillation, ventricular tachycardia, second or third degree heart block

2. Age greater than or equal to 60 years old

10. Documented forced expiratory volume (FEV1) less than or equal to 60% predicted tested
in patients with:

1. A prolonged history of cigarette smoking (20 pk/year of smoking within the past
2 years).

2. Symptoms of respiratory dysfunction